Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imatinib.

K Lyseng-Williamson1, B Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 6, 2001
PubMed
Summary
This summary is machine-generated.

Imatinib effectively treats Philadelphia chromosome-positive leukaemias and gastrointestinal stromal tumours. This tyrosine kinase inhibitor demonstrated significant haematological and cytogenetic responses in chronic myeloid leukaemia and acute lymphoblastic leukaemia patients, with notable clinical improvement in GIST.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2015
Same author

Application of Illumina next-generation sequencing to characterize the bacterial community of the Upper Mississippi River.

Journal of applied microbiology·2013
Same author

Stachybotrys: An unusual mold associated with water-damaged buildings.

Mycotoxin research·2013
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2010
Same author

On the compositing of samples for qualitative microbiological testing.

Letters in applied microbiology·2007
Same author

Estimates of measurement uncertainty from proficiency testing schemes, internal laboratory quality monitoring and during routine enforcement examination of foods.

Journal of applied microbiology·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Imatinib targets the BCR-ABL tyrosine kinase, a key driver in Philadelphia chromosome-positive (Ph+) leukaemias.
  • Standard chemotherapy had limited efficacy in certain advanced cancers, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of imatinib in patients with chronic myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL), and gastrointestinal stromal tumours (GIST).
  • To assess response rates across different phases of CML (chronic, accelerated, blast crisis) and in Ph+ ALL and GIST.

Main Methods:

  • Multicentre, noncomparative studies and a pilot study involving oral administration of imatinib at 400 or 600 mg/day.
  • Patient cohorts included individuals with chronic phase CML, accelerated phase CML, blast crisis CML, Ph+ ALL, and GIST unresponsive to standard chemotherapy.

Related Experiment Videos

Main Results:

  • High rates of complete haematological (88%) and major cytogenetic (49%) responses in chronic phase CML.
  • Significant haematological responses (63%) and major cytogenetic responses (21%) in accelerated phase CML.
  • Responses observed in blast crisis CML (13.5% major cytogenetic response), Ph+ ALL (haematological response in 19/32 patients), and GIST (89% clinical improvement).
  • Adverse events were common but mostly mild to moderate, with serious events including fluid retention, cytopenias, and hepatotoxicity.

Conclusions:

  • Imatinib demonstrates significant efficacy across various haematological malignancies and GIST.
  • The drug is a valuable therapeutic option for Ph+ leukaemias and imatinib-refractory GIST.
  • While adverse events occur, they are generally manageable, supporting imatinib's role in targeted cancer therapy.